WZWalter Zhao

Walter Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Walter Zhao has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhancing Study Design and Analysis of MR Imaging Markers Through Measurement Error Modeling

    by Xiaofeng Wang, Walter Zhao, Yifan Wang, Deborah H. Kwon, Ting‐Yu Su, Nancy A. Obuchowski, Mark A. Griswold, Zhong Irene Wang, Dan Ma

    Background: Measurement error in imaging reduces statistical power and potentially biases parameter estimation, compromising study reliability. Purpose: To introduce a dual data collection design (reliability and main datasets) to quantify measurement error and apply regression calibration to correct error‐prone imaging markers, thereby improving biomarker‐outcome estimation, statistical power, and sample size planning. Study Type: Prospective (reliability) and retrospective (regression calibration). Population: 65 healthy volunteers (mean age: 23.2), 60 age and sex matched with 34 epilepsy patients (mean age: 28.7). Field Strength/Sequence: 3.0 T, MR fingerprinting (MRF) and T1‐weighted (T1w) MPRAGE. Assessment: Three‐dimensional brain scan‐rescan data were acquired in 5 volunteers (6 identical acquisitions per volunteer across 3 scanners) to estimate reliability coefficients () for MRF T1 and T1w signal intensity (SI) mean and standard deviation (SD). These coefficients were applied in regression calibration to correct imaging markers in the epilepsy cohort. Effect sizes for distinguishing lesional from control were compared before and after correction. Simulations evaluated the impact of additive and proportional bias on sample size, statistical power, and association estimates under single and multi‐scanner scenarios. Statistical Test: Reliability coefficient, Cohen's d , regression calibration, generalized estimation equations. Results: MRF T1 markers exhibited higher reliability ( = 0.887–0.941) than T1w SI markers with site effects ( = 0.246–0.554). Regression calibration increased effect size more for T1w SI mean (333.22% increase) than for MRF T1 mean (12.57% increase). In multi‐site simulations, regression calibration alone achieved unbiased estimate under small site effects (additive and proportional SD ≤ 0.2), whereas under larger site effects (additive SD ≥ 0.5) only the combined regression calibration and Combat produced near‐zero bias (−0.024), outperforming naïve analysis (−0.423). Data Conclusion: The dual data acquisition design with regression calibration restores attenuated imaging biomarker associations, improves statistical power, and informs sampling requirements, thus enhancing reliability and generalizability in multi‐site imaging studies. Evidence Level: 3. Technical Efficacy: 2.


  • Open Access

    Contrast‐Enhanced MR Fingerprinting With Delta‐Relaxometry: Investigating a New Avenue for Tumor Characterization

    by Shengwen Deng, Walter Zhao, Sree Gongala, Jessie E. P. Sun, David W. Jordan, Chris A. Flask, Mark A. Griswold, Dan Ma, Chaitra Badve

    Background: MRI contrast agents enhance lesion characterization by altering tissue relaxation properties. However, quantitative assessment of contrast enhancement is limited by variability in contrast administration parameters, and lack of efficient and precise contrast concentration independent relaxivity ( r 1 , r 2 ) measurement techniques. MR Fingerprinting (MRF) rapidly, simultaneously and accurately measures T 1 and T 2 , enabling for the first time efficient clinical estimation of relaxivity ratios ( r 1 / r 2 ). Purpose: To introduce an MRF‐derived delta‐relaxometry method for mapping contrast‐specific relaxivity ratios ( r 1 / r 2 ) by accurately measuring Δ R 1 /Δ R 2 . We hypothesize that delta‐relaxometry ratios offer dose‐independent, reproducible measures of tissue enhancement, with potential advantages over conventional contrast‐enhanced MRI. Study Type: Prospective, observational. Population: Phantom studies and 29 patients (15 glioblastoma, 14 brain metastases). Field Strength/Sequence: 3 T; pre‐ and post‐contrast 3D whole‐brain MR Fingerprinting. Assessment: Mathematical derivations established a relationship between Δ R 1 /Δ R 2 and r 1 / r 2 . Phantom studies assessed the concentration‐dependency of Δ R 1 /Δ R 2 compared to Δ T 1 and Δ T 2 . Reproducibility was assessed by the inter‐subject coefficient of variation (CoV). In vivo tumor type differentiation was assessed with whole‐lesion histograms. Statistical Test: Coefficient of variation; coefficient of determination; Mann–Whitney U tests with Benjamini–Hochberg correction. Results: Δ R 1 /Δ R 2 is theoretically equivalent to r 1 / r 2 , showing contrast‐dose independence in phantom studies. Δ R 1 /Δ R 2 showed no dependence on injected dose or timing ( p > 0.05), unlike Δ T 1 and Δ T 2 . Delta‐relaxometry ratios were highly reproducible, selectively elevated in tumors versus normal tissue, and showed a difference between tumor core and edema ( p < 0.05). Δ R 1 /Δ R 2 showed higher intra‐subject reproducibility (median CoV: GBM = 27.3%, MET = 22.0%) as compared to Δ T 1 (GBM = 57.1%, MET = 106.2%; p < 0.001). Whole‐lesion histogram analysis of delta‐relaxometry ratios demonstrated GBM versus metastasis differentiation ( p < 0.05). “Data” Conclusions: In this proof‐of‐concept study, MRF‐derived Δ R 1 /Δ R 2 ratios show potential for reproducible, clinically feasible, dose‐independent relaxivity quantification. Delta‐relaxometry ratios may offer a novel approach to tissue characterization with minimal background enhancement, distinct from perfusion imaging. Our results suggest delta‐relaxometry as a tumor imaging marker worthy of further investigation. Evidence Level: 3 (retrospective cohort study with imperfectly applied reference standard). Technology Efficacy: 1 (feasibility study with quantitative assessment, requires a comparison with standard of care).

  • Open Access

    3D MR fingerprinting for dynamic contrast‐enhanced imaging of whole mouse brain

    by Yuran Zhu, Guanhua Wang, Yuning Gu, Walter Zhao, Jiahao Lu, Junqing Zhu, Christina J. MacAskill, Andrew Dupuis, Mark A. Griswold, Dan Ma, et al.

    Purpose: Quantitative MRI enables direct quantification of contrast agent concentrations in contrast‐enhanced scans. However, the lengthy scan times required by conventional methods are inadequate for tracking contrast agent transport dynamically in mouse brain. We developed a 3D MR fingerprinting (MRF) method for simultaneous T1 and T2 mapping across the whole mouse brain with 4.3‐min temporal resolution.Method: We designed a 3D MRF sequence with variable acquisition segment lengths and magnetization preparations on a 9.4T preclinical MRI scanner. Model‐based reconstruction approaches were employed to improve the accuracy and speed of MRF acquisition. The method's accuracy for T1 and T2 measurements was validated in vitro, while its repeatability of T1 and T2 measurements was evaluated in vivo (n = 3). The utility of the 3D MRF sequence for dynamic tracking of intracisternally infused gadolinium‐diethylenetriamine pentaacetic acid (Gd‐DTPA) in the whole mouse brain was demonstrated (n = 5).Results: Phantom studies confirmed accurate T1 and T2 measurements by 3D MRF with an undersampling factor of up to 48. Dynamic contrast‐enhanced MRF scans achieved a spatial resolution of 192 × 192 × 500 μm3 and a temporal resolution of 4.3 min, allowing for the analysis and comparison of dynamic changes in concentration and transport kinetics of intracisternally infused Gd‐DTPA across brain regions. The sequence also enabled highly repeatable, high‐resolution T1 and T2 mapping of the whole mouse brain (192 × 192 × 250 μm3) in 30 min.Conclusion: We present the first dynamic and multi‐parametric approach for quantitatively tracking contrast agent transport in the mouse brain using 3D MRF.


  • Open Access

    Efficient pulse sequence design framework for high‐dimensional MR fingerprinting scans using systematic error index

    by Siyuan Hu, Zhilang Qiu, Richard James Adams, Walter Zhao, Rasim Boyacioglu, Daniela Calvetti, Debra McGivney, Dan Ma

    Purpose: For effective optimization of MR fingerprinting (MRF) pulse sequences, estimating and minimizing errors from actual scan conditions are crucial. Although virtual‐scan simulations offer an approximation to these errors, their computational demands become expensive for high‐dimensional MRF frameworks, where interactions between more than two tissue properties are considered. This complexity makes sequence optimization impractical. We introduce a new mathematical model, the systematic error index (SEI), to address the scalability challenges for high‐dimensional MRF sequence design.Methods: By eliminating the need to perform dictionary matching, the SEI model approximates quantification errors with low computational costs. The SEI model was validated in comparison with virtual‐scan simulations. The SEI model was further applied to optimize three high‐dimensional MRF sequences that quantify two to four tissue properties. The optimized scans were examined in simulations and healthy subjects.Results: The proposed SEI model closely approximated the virtual‐scan simulation outcomes while achieving hundred‐ to thousand‐times acceleration in the computational speed. In both simulation and in vivo experiments, the optimized MRF sequences yield higher measurement accuracy with fewer undersampling artifacts at shorter scan times than the heuristically designed sequences.Conclusion: We developed an efficient method for estimating real‐world errors in MRF scans with high computational efficiency. Our results illustrate that the SEI model could approximate errors both qualitatively and quantitatively. We also proved the practicality of the SEI model of optimizing sequences for high‐dimensional MRF frameworks with manageable computational power. The optimized high‐dimensional MRF scans exhibited enhanced robustness against undersampling and system imperfections with faster scan times.


  • Open Access

    Self‐calibrated subspace reconstruction for multidimensional MR fingerprinting for simultaneous relaxation and diffusion quantification

    by Zhilang Qiu, Siyuan Hu, Walter Zhao, Ken Sakaie, Jessie E. P. Sun, Mark A. Griswold, Derek K. Jones, Dan Ma

    Purpose: To propose a new reconstruction method for multidimensional MR fingerprinting (mdMRF) to address shading artifacts caused by physiological motion‐induced measurement errors without navigating or gating.Methods: The proposed method comprises two procedures: self‐calibration and subspace reconstruction. The first procedure (self‐calibration) applies temporally local matrix completion to reconstruct low‐resolution images from a subset of under‐sampled data extracted from the k‐space center. The second procedure (subspace reconstruction) utilizes temporally global subspace reconstruction with pre‐estimated temporal subspace from low‐resolution images to reconstruct aliasing‐free, high‐resolution, and time‐resolved images. After reconstruction, a customized outlier detection algorithm was employed to automatically detect and remove images corrupted by measurement errors. Feasibility, robustness, and scan efficiency were evaluated through in vivo human brain imaging experiments.Results: The proposed method successfully reconstructed aliasing‐free, high‐resolution, and time‐resolved images, where the measurement errors were accurately represented. The corrupted images were automatically and robustly detected and removed. Artifact‐free T1, T2, and ADC maps were generated simultaneously. The proposed reconstruction method demonstrated robustness across different scanners, parameter settings, and subjects. A high scan efficiency of less than 20 s per slice has been achieved.Conclusion: The proposed reconstruction method can effectively alleviate shading artifacts caused by physiological motion‐induced measurement errors. It enables simultaneous and artifact‐free quantification of T1, T2, and ADC using mdMRF scans without prospective gating, with robustness and high scan efficiency.


  • Open Access

    Physics-Informed Discretization for Reproducible and Robust Radiomic Feature Extraction Using Quantitative MRI

    by Walter Zhao, Zheyuan Bs Hu, Anahita Fathi Kazerooni, Gregor Körzdörfer, Mathias Nittka, Christos Davatzikos, Satish E. Viswanath, Xiaofeng Wang, Chaitra Badve, Dan Ma

    Objective: Given the limited repeatability and reproducibility of radiomic features derived from weighted magnetic resonance imaging (MRI), there may be significant advantages to using radiomics in conjunction with quantitative MRI. This study introduces a novel physics-informed discretization (PID) method for reproducible radiomic feature extraction and evaluates its performance using quantitative MRI sequences including magnetic resonance fingerprinting (MRF) and apparent diffusion coefficient (ADC) mapping. Materials and Methods: A multiscanner, scan-rescan dataset comprising whole-brain 3D quantitative (MRF T1, MRF T2, and ADC) and weighted MRI (T1w MPRAGE, T2w SPACE, and T2w FLAIR) from 5 healthy subjects was prospectively acquired. Subjects underwent 2 repeated acquisitions on 3 distinct 3 T scanners each, for a total of 6 scans per subject (30 total scans). First-order statistical (n = 23) and second-order texture (n = 74) radiomic features were extracted from 56 brain tissue regions of interest using the proposed PID method (for quantitative MRI) and conventional fixed bin number (FBN) discretization (for quantitative MRI and weighted MRI). Interscanner radiomic feature reproducibility was measured using the intraclass correlation coefficient (ICC), and the effect of image sequence (eg, MRF T1 vs T1w MPRAGE), as well as image discretization method (ie, PID vs FBN), on radiomic feature reproducibility was assessed using repeated measures analysis of variance. The robustness of PID and FBN discretization to segmentation error was evaluated by simulating segmentation differences in brainstem regions of interest. Radiomic features with ICCs greater than 0.75 following simulated segmentation were determined to be robust to segmentation. Results: First-order features demonstrated higher reproducibility in quantitative MRI than weighted MRI sequences, with 30% (n = 7/23) features being more reproducible in MRF T1 and MRF T2 than weighted MRI. Gray level co-occurrence matrix (GLCM) texture features extracted from MRF T1 and MRF T2 were significantly more reproducible using PID compared with FBN discretization; for all quantitative MRI sequences, PID yielded the highest number of texture features with excellent reproducibility (ICC > 0.9). Comparing texture reproducibility of quantitative and weighted MRI, a greater proportion of MRF T1 (n = 225/370, 61%) and MRF T2 (n = 150/370, 41%) texture features had excellent reproducibility (ICC > 0.9) compared with T1w MPRAGE (n = 148/370, 40%), ADC (n = 115/370, 32%), T2w SPACE (n = 98/370, 27%), and FLAIR (n = 102/370, 28%). Physics-informed discretization was also more robust than FBN discretization to segmentation error, as 46% (n = 103/222, 46%) of texture features extracted from quantitative MRI using PID were robust to simulated 6 mm segmentation shift compared with 19% (n = 42/222, 19%) of weighted MRI texture features extracted using FBN discretization. Conclusions: The proposed PID method yields radiomic features extracted from quantitative MRI sequences that are more reproducible and robust than radiomic features extracted from weighted MRI using conventional (FBN) discretization approaches. Quantitative MRI sequences also demonstrated greater scan-rescan robustness and first-order feature reproducibility than weighted MRI.


  • Open Access

    Supplementary Data from Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

    by Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-Hua Wang, et al.

  • Open Access

    Supplementary Data from Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

    by Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-Hua Wang, et al.

  • Open Access

    Data from Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

    by Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-Hua Wang, et al.

    Purpose:We recently identified CD46 as a novel therapeutic target in prostate cancer. In this study, we developed a CD46-targeted PET radiopharmaceutical, [89Zr]DFO-YS5, and evaluated its performance for immunoPET imaging in murine prostate cancer models.Experimental Design:[89Zr]DFO-YS5 was prepared and its in vitro binding affinity for CD46 was measured. ImmunoPET imaging was conducted in male athymic nu/nu mice bearing DU145 [AR−, CD46+, prostate-specific membrane antigen–negative (PSMA−)] or 22Rv1 (AR+, CD46+, PSMA+) tumors, and in NOD/SCID gamma mice bearing patient-derived adenocarcinoma xenograft, LTL-331, and neuroendocrine prostate cancers, LTL-331R and LTL-545.Results:[89Zr]DFO-YS5 binds specifically to the CD46-positive human prostate cancer DU145 and 22Rv1 xenografts. In biodistribution studies, the tumor uptake of [89Zr]DFO-YS5 was 13.3 ± 3.9 and 11.2 ± 2.5 %ID/g, respectively, in DU145 and 22Rv1 xenografts, 4 days postinjection. Notably, [89Zr]DFO-YS5 demonstrated specific uptake in the PSMA- and AR-negative DU145 model. [89Zr]DFO-YS5 also showed uptake in the patient-derived LTL-331 and -331R models, with particularly high uptake in the LTL-545 neuroendocrine prostate cancer tumors (18.8 ± 5.3, 12.5 ± 1.8, and 32 ± 5.3 %ID/g in LTL-331, LTL-331R, and LTL-545, respectively, at 4 days postinjection).Conclusions:[89Zr]DFO-YS5 is an excellent PET imaging agent across a panel of prostate cancer models, including in both adenocarcinoma and neuroendocrine prostate cancer, both cell line- and patient-derived xenografts, and both PSMA-positive and -negative tumors. It demonstrates potential for clinical translation as an imaging agent, theranostic platform, and companion biomarker in prostate cancer.

  • Open Access

    Data from Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

    by Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-Hua Wang, et al.

    Purpose:We recently identified CD46 as a novel therapeutic target in prostate cancer. In this study, we developed a CD46-targeted PET radiopharmaceutical, [89Zr]DFO-YS5, and evaluated its performance for immunoPET imaging in murine prostate cancer models.Experimental Design:[89Zr]DFO-YS5 was prepared and its in vitro binding affinity for CD46 was measured. ImmunoPET imaging was conducted in male athymic nu/nu mice bearing DU145 [AR−, CD46+, prostate-specific membrane antigen–negative (PSMA−)] or 22Rv1 (AR+, CD46+, PSMA+) tumors, and in NOD/SCID gamma mice bearing patient-derived adenocarcinoma xenograft, LTL-331, and neuroendocrine prostate cancers, LTL-331R and LTL-545.Results:[89Zr]DFO-YS5 binds specifically to the CD46-positive human prostate cancer DU145 and 22Rv1 xenografts. In biodistribution studies, the tumor uptake of [89Zr]DFO-YS5 was 13.3 ± 3.9 and 11.2 ± 2.5 %ID/g, respectively, in DU145 and 22Rv1 xenografts, 4 days postinjection. Notably, [89Zr]DFO-YS5 demonstrated specific uptake in the PSMA- and AR-negative DU145 model. [89Zr]DFO-YS5 also showed uptake in the patient-derived LTL-331 and -331R models, with particularly high uptake in the LTL-545 neuroendocrine prostate cancer tumors (18.8 ± 5.3, 12.5 ± 1.8, and 32 ± 5.3 %ID/g in LTL-331, LTL-331R, and LTL-545, respectively, at 4 days postinjection).Conclusions:[89Zr]DFO-YS5 is an excellent PET imaging agent across a panel of prostate cancer models, including in both adenocarcinoma and neuroendocrine prostate cancer, both cell line- and patient-derived xenografts, and both PSMA-positive and -negative tumors. It demonstrates potential for clinical translation as an imaging agent, theranostic platform, and companion biomarker in prostate cancer.